Allogeneic Expanded Gamma Delta T Cells With GD2 Chemoimmunotherapy in Relapsed /Refractory Neuroblastoma or Refractory/ Relapsed Osteosarcoma

Abroad (travel likely)RecruitingPHASE1

Conditions

Neuroblastoma · Refractory Neuroblastoma · Relapsed Neuroblastoma · Relapsed Osteosarcoma · Refractory Osteosarcoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Children's Healthcare of Atlanta, Atlanta, Georgia, United States
Contact: Study coordinator (Kelly Goldsmith, MD) · mpactcto@choa.org

Study leads

Kelly Goldsmith, MD
Principal Investigator
Emory University

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors

Neuroblastoma · Sarcoma · Osteosarcoma

Abroad (travel likely)RecruitingPHASE1

Palo Alto, United States

Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas

Atypical Teratoid/Rhabdoid Tumor · Embryonal Tumor With Multilayered Rosettes · Ewing Sarcoma

Abroad (travel likely)RecruitingPHASE1, PHASE2

Birmingham, United States · Little Rock, United States

Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors

Neuroblastoma · Rhabdomyosarcoma · Synovial Sarcoma

Abroad (travel likely)RecruitingPHASE1, PHASE2

Gainesville, United States

Agnostic Therapy in Rare Solid Tumors

Urachal Cancer · Parathyroid Carcinoma · Fibrolamellar Carcinoma

Abroad (travel likely)RecruitingPHASE2

Fortaleza, Brazil · Salvador, Brazil